Metabolic Polymoryphisms, Smoking, and Oral Cancer in Puerto Rico

Authors: Xie, Heng1; Hou, Lifang2; Shields, Peter G.3; Winn, Deborah M.4; Gridley, Gloria2; Bravo-Otero, Eleuterio5; Diehl, Scott R.6; Bowman, Elise D.7; Brown, Linda M.2; Hayes, Richard B.2

Source: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Volume 14, Number 6, 2003 , pp. 315-320(6)

Publisher: Cognizant Communication Corporation

Buy & download fulltext article:

OR

Price: $79.00 plus tax (Refund Policy)

Abstract:

Genetic polymorphisms resulting in variation in metabolism of tobacco carcinogens may influence oral cancer risk. In a population-based case–control study in Puerto Rico, genotypes of CYP1A1, GSTM1, and GSTT1 were determined by a PCR-based method for 132 oral cancer patients and 143 control subjects. Genotype-associated risks were estimated by logistic regression. The null variant of GSTM1 was associated with a marginally significant decrease in oral cancer risk [odds ratio (OR) = 0.6, 95% confidence interval (CI) = 0.3–1.0, and P for trend = 0.09]. Risks increased with increasing cigarette use among subjects with the GSTM1-present genotype (P for trend <0.0001), rising to OR = 9.5, 95% CI = 3.0–30, among the heaviest cigarette users. In contrast, among subjects with the GSTM1-null genotype, risks did not clearly increase with increasing cigarette use (P for trend <0.61; OR = 1.8, 95% CI = 0.6–5.2 among the heaviest tobacco users). The GSTT1-null variant (OR = 1.0, 95% CI = 0.5–1.9) and CYP1A1462Val variant (OR = 0.9, 95% CI = 0.5–1.7) were not associated with the risk. Risks rose with increasing cigarette use in a similar manner for subjects with or without the CYP1A1462Val variant (P for interaction = 0.3) and for subjects with or without the GSTT1-null genotype (P for interaction = 0.4). In conclusion, cigarette use significantly increased the risk of oral cancer in this population. The GSTM1-present genotype was associated with higher tobacco-associated risk for oral cancer among heavy smokers than the null genotype.

Keywords: Carcinoma; Enzymes; Polymorphism; Smoking

Document Type: Research Article

DOI: http://dx.doi.org/10.3727/096504003773994851

Affiliations: 1: *Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892 2: †Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 3: ¶Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007 4: ‡Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 5: #School of Dentistry, University of Puerto Rico, San Juan, PR 00936-5067 6: **Center for Pharmacogenomics and Complex Disease Research, New Jersey Dental School, UMDNJ, Newark, NJ 07101-1709 7: §Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, MD 20892

Publication date: January 1, 2003

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page